COPD Management for Nurses

COPD is an umbrella term encompassing two primary clinical presentations — chronic bronchitis and emphysema — that frequently coexist. The defining feature is persistent, incompletely reversible airflow obstruction, differentiating COPD from asthma where obstruction is typically reversible.

Tobacco smoking is the primary cause in developed countries, accounting for approximately 85–90% of cases. Other causes include occupational dust/chemical exposure, indoor air pollution (biomass fuel), and alpha-1 antitrypsin deficiency.

• Dyspnea: Progressive, worsening with exertion; hallmark complaint. Rated using the modified Medical Research Council (mMRC) scale.
• Chronic cough: Often productive with clear-to-yellow sputum. Purulent sputum change may signal infection/exacerbation.
• Barrel chest: Increased AP diameter from chronic air trapping and hyperinflation; ribs appear horizontal.
• Pursed-lip breathing: Creates back-pressure to keep airways open during exhalation — increases expiratory time and reduces air trapping.
• Diminished breath sounds: From hyperinflated lung fields and destroyed alveoli. Wheezes and prolonged expiratory phase.
• Accessory muscle use: Sternocleidomastoid and scalene recruitment indicates increased work of breathing.
• Clubbing: Chronic hypoxemia. Cor pulmonale (right HF from pulmonary hypertension) in advanced disease.

Oxygen therapy in COPD requires careful titration. The classic teaching of the “hypoxic drive” (administering high O₂ suppresses the respiratory drive) is an oversimplification, but the concern is clinically relevant in a subset of severe COPD patients with chronic CO₂ retention.

• Nasal cannula: 1–2 L/min typically achieves SpO₂ 88–92% in stable COPD; preferred for comfort and ability to eat/speak
• Venturi mask: Delivers precise, controlled FiO₂ (24–40%); preferred when reliable FiO₂ delivery is critical, as in acute exacerbations with CO₂ retention risk
• NPPV (BiPAP): First-line for acute hypercapnic respiratory failure in COPD exacerbations — reduces intubation rate and mortality
• Monitoring: Continuous SpO₂, respiratory rate and effort, mental status, and ABGs as indicated. Watch for CO₂ narcosis: somnolence, confusion, decreasing RR

An acute exacerbation of COPD (AECOPD) is a sudden worsening of respiratory symptoms beyond normal day-to-day variation. Early recognition is critical to prevent hospitalization and respiratory failure.

Hallmark signs of exacerbation:

• Increased dyspnea — worse than baseline, often at rest
• Change in sputum: increased volume, thicker consistency, or new purulence (green/yellow)
• New or worsening wheezing and prolonged expiration
• Decreased SpO₂ below patient baseline or below 88%
• Use of accessory muscles, paradoxical chest movement in severe cases
• Altered mental status — a late, serious sign of CO₂ retention and impending failure

Common triggers:

• Respiratory infections (most common): viral URIs, bacterial pneumonia
• Air pollution, cold air, smoke exposure
• Medication non-adherence
• Heart failure exacerbation (biventricular failure common in COPD)
• Pulmonary embolism

Patients with advanced COPD often have chronic respiratory acidosis with metabolic compensation — their baseline ABG differs significantly from normal values:

When evaluating ABGs in COPD, always compare to the patient's known baseline. An acute rise in PaCO₂ above the patient's chronic baseline with an acute pH drop indicates acute-on-chronic respiratory failure — a medical emergency requiring immediate NPPV or intubation.

Supplemental oxygen in hypercapnic COPD: oxygen eliminates the hypoxic vasoconstriction reflex, worsening V/Q mismatch (Haldane effect), and can blunt the residual hypoxic drive — titrate carefully.

• Oxygenation: Titrate O₂ to maintain SpO₂ 88–92% unless otherwise ordered. Avoid uncontrolled high-flow O₂ in known hypercapnic COPD.
• Respiratory assessment: RR, depth, effort, accessory muscle use, breath sounds, SpO₂ every 1–4 hours depending on acuity. Trending changes are as important as single values.
• Position: High-Fowler's or tripod; elevate HOB 30–45 degrees. Never supine if dyspneic.
• Medications: Administer bronchodilators (SABA, LABA, anticholinergics) and corticosteroids as ordered. Ensure proper inhaler technique. Coordinate nebulizer treatments with respiratory therapy.
• Secretion management: Encourage hydration, incentive spirometry, coughing and deep breathing exercises, and controlled cough technique. Chest physiotherapy as ordered.
• Smoking cessation: Every hospitalization is an opportunity. Screen, advise, and refer to cessation resources. Brief intervention (5 As: Ask, Advise, Assess, Assist, Arrange) is effective.
• Mental status: CO₂ narcosis presents as somnolence, confusion, or decreased RR — notify provider immediately.

• Target SpO₂ in COPD: 88–92% (not 94–98%)
• Venturi mask provides the most precise FiO₂ delivery for COPD patients
• Pursed-lip breathing keeps small airways open and reduces air trapping
• “Pink Puffer” = emphysema; “Blue Bloater” = chronic bronchitis
• Barrel chest = hyperinflation from air trapping (emphysema)
• Somnolence + low RR in COPD patient on O₂ = CO₂ narcosis — reduce O₂, notify provider
• Tripod position reduces work of breathing in acute dyspnea
• BiPAP/NPPV is the preferred intervention for acute hypercapnic COPD exacerbation